The technology pertains to the potential and utility of TARBP-BTP, a new fusion protein that fosters the efficient delivery of siRNA to the brain and hence mediate the knockdown of target genes responsible for early onset of neurodegenerative disorders and would also serve unmet needs for incurable neurological conditions. e.g. Huntington's Disease, Alzheimer's Disease (AD).
Accessibility Controls